National Cancer Institute; Notice of Closed Meeting, 25020-25021 [E8-9879]
Download as PDF
25020
Federal Register / Vol. 73, No. 88 / Tuesday, May 6, 2008 / Notices
20892–8329, 301/496–7987,
lovingeg@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Molecular
and Cellular Oncology.
Date: June 4–5, 2008.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Michael B. Small, PhD,
Scientific Review Officer, Division of
Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116
Executive Blvd., Room 8127, Bethesda, MD
20892–8328, 301–402–0996,
smallm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 29, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–9874 Filed 5–5–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
rwilkins on PROD1PC63 with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Cancer Institute Board of
Scientific Advisors.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Cancer
Institute Board of Scientific Advisors.
Date: June 23–24, 2008.
Time: June 23, 2008, 8 a.m. to 6 p.m.
Agenda: Director’s Report: Ongoing and
New Business; Reports of Program Review
Group(s); and Budget Presentation; Reports of
Special Initiatives; RFA and RFP Concept
Reviews; and Scientific Presentations.
Place: National Institutes of Health,
Building 31, 31 Center Drive, 6th Floor,
Conference Room 10, Bethesda, MD 20892.
Time: June 24, 2008, 8:30 a.m. to 12 p.m.
VerDate Aug<31>2005
17:11 May 05, 2008
Jkt 214001
Agenda: Reports of Special Initiatives; RFA
and RFP Concept Reviews; and Scientific
Presentations.
Place: National Institutes of Health,
Building 31, 31 Center Drive, 6th Floor,
Conference Room 10, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, PhD,
Executive Secretary, Director, Division of
Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Rm. 8001,
Bethesda, Md 20892, 301–496–5147,
grayp@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/bsa.htm, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 29, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–9875 Filed 5–5–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
G—Education.
Date: June 24, 2008.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crowne Plaza Washington Silver
Spring, 8777 Georgia Ave., Silver Spring, MD
20910.
Contact Person: Sonya Roberson, PhD,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8109,
Bethesda, MD 20892, 301–594–1182,
robersos@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 29, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–9877 Filed 5–5–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
J—Population and Patient-Oriented Training;
Population and Patient-Oriented Training.
E:\FR\FM\06MYN1.SGM
06MYN1
Federal Register / Vol. 73, No. 88 / Tuesday, May 6, 2008 / Notices
Date: June 17, 2008.
Time: 7:45 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westin Tysons Corner, 7801
Leesburg Pike, Falls Church, VA 22043.
Contact Person: Ilda M. Mckenna, PhD,
Scientific Review Officer, Research Training
Review Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Boulevard, Room 8111, Bethesda,
MD 20892, 301–496–7481,
mckennai@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 29, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–9879 Filed 5–5–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Antibody Therapeutics for the
Treatment of Cancer in Humans
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
rwilkins on PROD1PC63 with NOTICES
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the invention
embodied in U.S. Patent Application
Number 11/895,326, filed August 24,
2007, entitled ‘‘Tumor Markers in
Ovarian Cancer’’ [E–138–2000/0–US–
05]; to Morphotek, Incorporated, having
a place of business at Exton, PA. The
patent rights in these inventions have
been assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to antibodies
developed by Licensee’s proprietary
Human MORPHODOMA antibody
technology or via humanization for anticlaudin-3 antibody therapeutics for
ovarian cancer.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
VerDate Aug<31>2005
17:11 May 05, 2008
Jkt 214001
25021
Technology Transfer on or before July 7,
2008 will be considered.
DEPARTMENT OF HOMELAND
SECURITY
Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Jennifer Wong,
Technology Licensing Specialist, Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
4633; Facsimile: (301) 402–0220; E-mail:
wongje@mail.nih.gov.
Transportation Security Administration
ADDRESSES:
The
technology relates to claudin-3 as an
ovarian cancer biomarker. Claudin-3
was identified as a biomarker utilizing
SAGE analysis comparing ovarian
epithelial tumor cells and normal
ovarian epithelial cells. Claudin-3 is a
member of a family of transmembrane
proteins associated with tight junctions
and its function has been associated
with invasive ovarian cancer. Inhibition
of claudin-3 is a potential therapeutic
for the treatment of metastatic ovarian
cancer.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
SUPPLEMENTARY INFORMATION:
Dated: April 29, 2008.
David Sadowski,
Deputy Director, Division of Technology
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.
[FR Doc. E8–9873 Filed 5–5–08; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
[Docket Nos. TSA–2006–24191; Coast
Guard–2006–24196]
Transportation Worker Identification
Credential (TWIC); Enrollment Dates
for the Ports of Houma, LA; Morgan
City, LA; Calcite, MI; San Francisco,
CA; and Kansas City, MO
Transportation Security
Administration; United States Coast
Guard; DHS.
ACTION: Notice.
AGENCY:
SUMMARY: The Department of Homeland
Security (DHS) through the
Transportation Security Administration
(TSA) issues this notice of the dates for
the beginning of the initial enrollment
for the Transportation Worker
Identification Credential (TWIC) for the
Ports of Houma, LA; Morgan City, LA;
Calcite, MI; San Francisco, CA; and
Kansas City, MO.
DATES: TWIC enrollment begins in
Houma on May 7, 2008; Morgan City on
May 9, 2008; Calcite and San Francisco
on May 14, 2008; and Kansas City on
May 15, 2008.
ADDRESSES: You may view published
documents and comments concerning
the TWIC Final Rule, identified by the
docket numbers of this notice, using any
one of the following methods.
(1) Searching the Federal Docket
Management System (FDMS) Web page
at https://www.regulations.gov;
(2) Accessing the Government
Printing Office’s Web page at https://
www.gpoaccess.gov/fr/; or
(3) Visiting TSA’s Security
Regulations Web page at https://
www.tsa.gov and accessing the link for
‘‘Research Center’’ at the top of the page.
FOR FURTHER INFORMATION CONTACT:
James Orgill, TSA–19, Transportation
Security Administration, 601 South
12th Street, Arlington, VA 22202–4220.
Transportation Threat Assessment and
Credentialing (TTAC), TWIC Program,
(571) 227–4545; e-mail:
credentialing@dhs.gov.
Background
The Department of Homeland
Security (DHS), through the United
States Coast Guard and the
Transportation Security Administration
(TSA), issued a joint final rule (72 FR
3492; January 25, 2007) pursuant to the
Maritime Transportation Security Act
(MTSA), Pub. L. 107–295, 116 Stat. 2064
(November 25, 2002), and the Security
and Accountability for Every Port Act of
E:\FR\FM\06MYN1.SGM
06MYN1
Agencies
[Federal Register Volume 73, Number 88 (Tuesday, May 6, 2008)]
[Notices]
[Pages 25020-25021]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-9879]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Initial Review
Group; Subcommittee J--Population and Patient-Oriented Training;
Population and Patient-Oriented Training.
[[Page 25021]]
Date: June 17, 2008.
Time: 7:45 a.m. to 6 p.m.
Agenda: To review and evaluate grant applications.
Place: The Westin Tysons Corner, 7801 Leesburg Pike, Falls
Church, VA 22043.
Contact Person: Ilda M. Mckenna, PhD, Scientific Review Officer,
Research Training Review Branch, Division of Extramural Activities,
National Cancer Institute, 6116 Executive Boulevard, Room 8111,
Bethesda, MD 20892, 301-496-7481, mckennai@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: April 29, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-9879 Filed 5-5-08; 8:45 am]
BILLING CODE 4140-01-P